Snowden Capital Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Snowden Capital Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$366K	Buy	1,286 +89	+7%	+$26.2K	0.01%	985
2026 Q1	$355K	Buy	1,197 +255	+27%	+$82.5K	0.01%	950
2025 Q4	$286K	Sell	942 -49	-5%	-$16K	0.01%	1065
2025 Q3	$338K	Buy	991 +68	+7%	+$20.6K	0.01%	968
2025 Q2	$223K	Buy	923 +27	+3%	+$6.62K	0.01%	1134
2025 Q1	$244K	Buy	+896	New	+$209K	0.01%	1073
2024 Q4	–	Sell	-961	Closed	-$216K	–	1272
2024 Q3	$216K	Buy	+961	New	+$173K	0.01%	1142

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Snowden Capital Advisors's ONC Position: Q2 2026 in Review

Snowden Capital Advisors increased its BeOne Medicines Ltd (ONC) stake by 7.4% in Q2 2026, buying an estimated $26.2K and bringing the position to 1,286 shares worth $366K. The position accounts for 0.01% of the portfolio, ranked #985.

Snowden Capital Advisors first reported a position in ONC in Q3 2024 and has held it in 7 quarters since. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Snowden Capital Advisors held 1,286 shares of BeOne Medicines Ltd worth $366K as of Q2 2026.
Snowden Capital Advisors bought 89 BeOne Medicines Ltd shares in Q2 2026, an estimated $26.2K.
BeOne Medicines Ltd made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #985 holding.
Snowden Capital Advisors first reported a position in BeOne Medicines Ltd in Q3 2024 and has held it in 7 quarters since.
283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.